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Background: We aimed to determine the risk of
recurrence for symptomatic venous thromboembolism
(VTE) provoked by different transient risk factors.
Data Sources:MEDLINE, EMBASE, and Cochrane Col-
laboration Registry of Randomized Trials databases were
searched.
Study Selection: Prospective cohort studies and ran-
domized trials of patients with a first episode of symp-
tomatic VTE provoked by a transient risk factor and
treated for at least 3 months were identified.
Data Extraction: Number of patients and recurrent
VTE during the 0- to 12-month and 0- to 24-month
intervals after stopping therapy, study design,
and provoking risk factor characteristics were
extracted.
Data Synthesis: Annualized recurrence rates were cal-
culated and pooled across studies. At 24 months, the rate
of recurrence was 3.3% per patient-year (11 studies, 2268
patients) for all patients with a transient risk factor, 0.7%
per patient-year (3 studies, 248 patients) in the subgroup
with a surgical factor, and4.2%perpatient-year (3 studies,
509patients) in the subgroupwith a nonsurgical factor. In
the same studies, the rate of recurrence after unprovoked
VTEwas7.4%perpatient-year.The rate ratio for anonsur-
gical comparedwithasurgical factorwas3.0andforunpro-
voked thrombosis comparedwith anonsurgical factorwas
1.8 at 24 months.
Conclusions: The risk of recurrence is low if VTE is pro-
voked by surgery, intermediate if provoked by a nonsurgi-
cal risk factor, and high if unprovoked. These risks affect
whether patients with VTE should undergo short-term vs
indefinite treatment.
Arch Intern Med. 2010;170(19):1710-1716
V ENOUS THROMBOEMBO-lism (VTE) is associatedwith diverse risk factors,some of which are tran-sient, such as recent sur-
gery and pregnancy, and others of which
are persistent, such as cancer.When VTE
is associated with an acquired risk factor,
either transient or persistent, it is called
provoked.When there is no apparent clini-
cal risk factor, it is called unprovoked or
idiopathic.1
It has recently been recognized that the
presence or absence of a transient, or re-
versible, risk factor at the time of VTE
strongly affects the risk of recurrence af-
ter anticoagulant therapy is stopped. Pa-
tients with VTE provoked by a transient
risk factor have a low risk of recurrence
compared with patients with either VTE
provoked by a persistent risk factor or un-
provoked VTE.2-6 For this reason, pa-
tients with VTE provoked by a transient
risk factor are usually treated with anti-
coagulant agents for 3 months,1 whereas
patients with VTE that was not associ-
ated with a transient risk factor are often
treated long-term.1 Although it is widely
accepted that the risk of recurrence in pa-
tients with VTE provoked by a transient
risk factor is low enough to justify stop-
ping anticoagulant therapy after 3months,
this recurrence risk is not well quanti-
fied. Furthermore, the risk of recurrence
may not be the same in all patients with
VTE provoked by a transient risk factor;
those with VTE provoked by recent sur-
gery seem to have a lower risk of recur-
rence than do those with VTE provoked
by anonsurgical risk factor, such as amedi-
cal illness.6
We performed a systematic review of
the literature to quantify the risk of recur-
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rence after stopping anticoagulant
therapy in patients with a first epi-
sode of symptomatic VTE (index
VTE) that was provoked by any re-
versible risk factor and to compare
the risk of recurrence according to
whetherVTEwas associatedwith re-
cent surgery orwith a transient non-
surgical risk factor. We considered
it important to identify the risk of
recurrence in the subgroup of pa-
tients with VTE provoked by a non-
surgical transient risk factor be-
cause it remains unclear whether
these patients should be treated in
a similar manner as those with sur-
gically provoked events (ie, short-
term anticoagulation) or whether
their risk of recurrence is high
enough to justify long-term antico-
agulation.
The primary objective of this sys-
tematic review was to determine
rates of first recurrent VTE after
stopping anticoagulant therapy in
patients who had completed 3 or
moremonths of treatment for an in-
dex VTE provoked by (1) any tran-
sient risk factor, (2) surgery, or (3)
a nonsurgical factor. Secondary ob-
jectives were to determine whether
study design and quality (ie, ran-
domized controlled trial vs obser-
vational cohort study and prospec-
tive vs retrospective categorization
of patients as having a reversible risk
factor) affected these rates and to
compare rates of recurrence in pa-
tients with index VTE provoked by
a transient risk factor with rates of
recurrence in patients with unpro-
voked index VTE enrolled in the
same studies.
METHODS
DATA SOURCES
AND SEARCHES
The following databases were searched:
MEDLINE(PubMed, 1966 to June2008),
EMBASE (http://www.embase.com, 1980
to June 2008), and Cochrane Collabora-
tionRegistryofRandomizedTrials (CEN-
TRAL,Wiley 2008 edition). Nomethod-
ological filters and language or date
restrictions were applied. Searches in-
cluded the following text words and in-
dex terms: anticoagulant, anticoagula-
tion,warfarin,Coumadin, coumarin, venous
thromboembolism, pulmonary embolism/
incidence, pulmonary embolism/recur-
rence, pulmonary embolism/epidemiology,
venous thrombosis/complications, venous
thrombosis/drug therapy, venous thrombo-
sis/epidemiology, venous thrombosis/
prevention, and control. The references of
retrieved articles, including related guide-
lines and systematic reviews, were
scanned for additional relevant studies.
STUDY SELECTION
Two reviewers (A.I. and E.F.) indepen-
dently screened all articles using a stan-
dard form, and disagreements were re-
solved by a third person (M.M.). For
studies to be eligible for the present
analysis, they had to satisfy all the fol-
lowing criteria: (1) enrolled patients (all
patients or a subgroup) had a first epi-
sode of objectively confirmedVTE (deep
venous thrombosis [DVT] or pulmo-
nary embolism [PE]) provokedby a tran-
sient risk factor, and the definition of a
transient risk factor was provided (pa-
tients with cancer are not included, even
if they had VTE provoked by an addi-
tional transient risk factor); (2) pa-
tients were treated for at least 3 months
with oral anticoagulant agents; (3) pa-
tients were observed prospectively af-
ter stopping anticoagulant therapy; (4)
first recurrent VTE was systematically
assessed during follow-up and diag-
nosed using objective testing; and (5) the
recurrence rate was reported in the ar-
ticle or data were reported that enabled
its calculation or estimation.
DATA EXTRACTION
AND QUALITY ASSESSMENT
The following data were extracted from
eligible studies: (1) the number of pa-
tients with index VTE provoked by a
transient risk factor, subcategorized as
provoked by a surgical or a nonsurgical
factor, when this information was avail-
able; (2) whether patients with unpro-
voked index VTE were also included in
the study, and the number of such pa-
tients; (3) the number of first episodes
of recurrent VTE after stopping antico-
agulant therapy for each group of pa-
tients, subcategorized as during fol-
low-up from 0 to 12months and 0 to 24
months (follow-up beyond 24 months
after stopping anticoagulant therapywas
excluded from this analysis); (4) the
number of patient-years of follow-up af-
ter stopping anticoagulant drug therapy
for each group of patients, subcatego-
rized as during follow-up from 0 to 12
months and 0 to 24months; (5) the cri-
teria used to categorize patients as hav-
ing index VTE provoked by a transient
risk factor; (6) the proportion of pa-
tients in each subgroup who were fe-
male; (7) whether the patients were en-
rolled in a randomized trial or a
prospective cohort study; and (8)
whether classification of the patients as
having a provoked or unprovoked in-
dex VTE was performed prospectively
or retrospectively.
DATA SYNTHESIS
AND ANALYSIS
The rate of recurrence, with its 95%
confidence interval (CI), was calcu-
lated for each group in each study from
the number of episodes of VTE that
occurred during the corresponding
total number of patient-years of
follow-up and is expressed as an annu-
alized percentage probability of events
(eg, 6 episodes in 400 patient-years
corresponds to a rate of 1.5% per
patient-year). Whenever possible, the
annualized rate was calculated for the
first year and for the first 2 years (in-
cludes the first year) after anticoagu-
lant therapy was stopped. If these data
were not reported directly, they were
estimated from the data that were pro-
vided, with the assumption that
patients who did not complete a
follow-up period (eg, died or were lost
to follow-up) were observed for half of
that interval. Annualized recurrence
rates in individual studies were com-
bined to obtain pooled estimates of
recurrence rates using the method of
Laird and Mosteller.7 A fixed-effects or
a random-effects model was used
depending on whether heterogeneity
was present (Cochran Q !2 with
P" .05 or I2"50%), with inverse vari-
ance weighting. In the comparison of 2
populations of patients, provided data
were available for the 2 populations in
at least 3 studies; rate ratios (with their
95% CIs) were calculated in each study
and then combined. If only 2 studies
were available, the number of events
and the number of patient-years of
follow-up in each subgroup were
directly combined to estimate overall
event rates in the relevant population;
these rates were then used to estimate
rate ratios between subgroups. Calcu-
lations were produced using Compre-
hensive Meta-Analysis version 2.0
(Biostat, Englewood, New Jersey) and
forest plots usingMIX version 1.7 (http:
/ /www.meta-analysis-made-easy
.com/).8
RESULTS
LITERATURE SEARCH
The literature search yielded 1089
references, from which 15 articles
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were eligible for the analysis.2-6,9-18
Details about the study selectionpro-
cedure are given in Figure 1. Thir-
teen2-6,9,10,12-16,18 of the 15 studies re-
ported data for the 0- to 12-month
interval and 114-6,9-11,14-18 reported
data for the 0- to 24-month inter-
val. Seven studies2,3,6,9-12 reported raw
numbers of recurrent VTE events,
and we estimated these data in 8
studies.4,5,13-18 Additional details are
given in Table 1.
PATIENT CHARACTERISTICS
Table 1 provides the categories of
patients enrolled in each study;
Table 2 lists the definitions of sur-
gical and nonsurgical trigger events
as reported in the source studies.
CHARACTERISTICS
OF THE QUALIFYING VTE
Venous thromboembolism was
symptomatic in all the studies. One
study12 also included a small pro-
portion (9%) of patientswith asymp-
tomatic DVT diagnosed bymeans of
venographic screening after ortho-
pedic surgery. The mode of presen-
tation (eg, DVT or PE) of the index
VTE was usually reported for the
whole population in a study rather
than for each subgroup of patients.
In 4 studies2,3,9,12 that included 569
index VTEs provoked by a tran-
sient risk factor, 29% were proxi-
mal DVT, 5%were distal DVT, 33%
wereDVTof unspecified extent, 22%
were PEwithout symptomatic DVT,
and 11% were PE with sympto-
matic DVT.
VTE PROVOKED BY ANY
TRANSIENT RISK FACTOR
During the first 12 months after
stopping anticoagulant therapy,
there were 96 recurrent VTEs in
2387patients (2273patient-years; 13
studies2-6,9,10,12-16,18) who had an in-
dex VTE provoked by any tran-
sient risk factor, corresponding to an
annualized event rate of 3.1%per pa-
tient-year (95% CI, 2.0%-4.2% per
patient-year, random-effects model;
Cochran Q, P=.02 and I2=51% for
heterogeneity) (Figure 2A). Dur-
ing the 0- to 24-month interval af-
ter stopping anticoagulant therapy,
there were 150 recurrent VTEs in
2268patients (4186patient-years; 11
studies4-6,9-11,14-18) who had an in-
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References
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Figure 1. Flowchart of the study selection procedure showing the number of references at each stage.
The embedded table lists the number of studies providing data (reported or estimable) at the 2 follow-up
lengths analyzed.
Table 1. Study and Patient Characteristicsa
Source Design
No. of Patients
VKAs
Duration,
mo Surgery
Nonsurgical Risk Factors Outcome
Proportion
Female
Provoked
VTE
Unprovoked
VTE Trauma Plaster Medical
Bed
Rest Pregnancy Puerperium
OC/
HRT
At
12 mo
At
24 mo
Schulman et al,9 1985 RCT 10 35 3-60 E E NA NA E NA NA E R R NA
BTS,2 1992 RCT 56 298 3 R NA NA NA NA NA NA NA R NA 0.49
Schulman et al,4 1995 RCT 167 287 6 NA NA NA NA NA NA NA NA E E 0.43
Levine et al,3 1995 RCT 84 NA 3 E NA NA NA E NA NA NA R NA 0.45
Hansson et al,5 2000 Obs 195 NA 6 R NA NA NA R R NA NA E E 0.53
Palareti et al,10 2002 Obs 185 166 5 R R R NA R R NA R R R 0.50
Prandoni et al,11 2002 Obs 109 124 3-12 E E E NA NA E NA E NA R 0.53
Baglin et al,6 2003 Obs 377 193 3 R NA R R R R R R R R 0.56
Kearon et al,12 2004 RCT 81 NA 3 E NA E NA E NA NA NA R NA 0.47
Cushman et al,13 2004 Obs 82 116 NA NA NA NA NA NA NA NA NA R NA 0.52
Christiansen et al,14 2005 Obs 215 256 3-96 E E E NA E E E E E E 0.57
García-Fuster et al,15 2005 Obs 43 NA 6 E NA NA NA E NA NA E E E 0.49
Prandoni et al,16 2007 Obs 762 864 3-36 E E E E NA E NA E R E 0.55
Poli et al,17 2007 Obs 75 107 7 NA NA NA NA NA NA NA NA NA E 0.43
Baglin et al,18 2008 Obs 130 142 6 NA E E E E NA NA E NA E 0.48
Abbreviations: BTS, Research Committee of the British Thoracic Society; Obs, observational; OC/HRT, oral contraceptive/hormone therapy; RCT, randomized
controlled trial; VKAs, vitamin K antagonists; VTE, venous thromboembolism.
a“R” indicates that outcomes for subset data, or overall outcomes at 12 or 24 months, are directly reported; “E,” that outcomes for subset data, or overall
outcomes at 12 and 24 months, are estimated from the reported data as detailed in the “Methods” subsection of the main text; and NA, that subset data or
outcomes at 12 or 24 months were not available.
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dex VTE provoked by any tran-
sient risk factor, corresponding to an
annualized event rate of 3.3%per pa-
tient-year (95% CI, 2.8%-3.9% per
patient-year, fixed-effects model;
Cochran Q, P=.32 and I2=13% for
heterogeneity) (Figure 2B).
VTE PROVOKED BY SURGERY
During the first 12 months after
stopping anticoagulant therapy,
there were 2 recurrent VTEs in 243
patients (234 patient-years; 3 stud-
ies2,5,6) with index VTE provoked by
surgery, corresponding to an annu-
alized event rate of 1.0%per patient-
year (95%CI, 0%-2.3% per patient-
year, fixed-effects model; Cochran
Q, P=.67 and I2=0% for heteroge-
neity). During the 0- to 24-month
interval after stopping anticoagu-
lant therapy, there were 5 recur-
rent VTEs in 248 patients (443 pa-
tient-years; 3 studies5,6,10) with an
indexVTEprovokedby surgery, cor-
responding to an annualized event
rate of 0.7% per patient-year (95%
CI, 0%-1.5% per patient-year, fixed-
effectsmodel; CochranQ,P=.33 and
I2=10% for heterogeneity).
VTE PROVOKED
BY A NONSURGICAL FACTOR
During the first 12 months after
stopping anticoagulant therapy,
therewere 20 recurrent VTEs in 385
patients (347 patient-years; 2 stud-
ies5,6) with an index VTE provoked
by a nonsurgical factor, correspond-
ing to an annualized event rate of
5.8%per patient-year (95%CI, 3.2%-
8.3% per patient-year, fixed-effects
model; CochranQ,P=.89 and I2=0%
for heterogeneity). During the 0- to
24-month interval after stopping an-
ticoagulant therapy, there were 36
episodes of recurrent VTE in 509 pa-
tients (833 patient-years; 3 stud-
ies5,6,10) with an index VTE pro-
voked by a nonsurgical factor,
corresponding to an annualized
event rate of 4.2% per patient-year
(95% CI, 2.8%-5.6% per patient-
year, fixed-effects model; Cochran
Q, P=.68 and I2=0% for heteroge-
neity). The rate ratio for the recur-
rence of VTE provoked by a non-
surgical trigger compared with that
provoked by recent surgery was 3.7
(95% CI, 0.9-15.5, fixed-effects1
model; CochranQ,P=.45 and I2=0%
for heterogeneity) at 1 year (2 stud-
ies5,6) and 3.0 (95% CI, 1.1-8.1,
fixed-effects model; Cochran Q,
P= .50 and I2= 0% for heteroge-
neity) at 2 years (3 studies5,6,10).
STUDY DESIGN AND QUALITY
Analyses were performed to assess
whether differences in study de-
sign and quality affected study find-
ings and accounted for hetero-
geneity among studies. Eleven
studies2,4-6,9,11,12,15-18 prospectively
categorized the qualifying VTE as
provoked or unprovoked, whereas
this categorization was done retro-
spectively in 4 studies.3,10,13,14 At 12
months, the recurrence rate after
VTEprovokedby a transient risk fac-
tor was 3.5% per patient-year (95%
CI, 2.1%-4.9% per patient-year, ran-
dom-effects model; Cochran Q,
P= .03 and I2=52% for heteroge-
neity) for prospective studies and
2.1%per patient-year (95%CI, 0.9%-
3.4% per patient-year, fixed-effects
model; CochranQ,P=.38 and I2=2%
for heterogeneity) for retrospective
studies. The Cochran Q test for
heterogeneity between studies of dif-
ferent design was not significant
(P=.15). At 24 months, the annu-
alized recurrence rate was 3.7% per
patient-year (95%CI, 3.0%-4.3%per
patient-year; CochranQ, P=.55 and
I2=0% for heterogeneity) for pro-
spective studies and 2.3% per pa-
tient-year (95% CI, 1.2%-3.4% per
patient-year; CochranQ, P=.73 and
I2=0% for heterogeneity) for retro-
spective studies. TheCochranQ test
for heterogeneity between studies of
different design was significant
(P=.03).
Ten of the studies were prospec-
tive observational studies5,6,10,11,13-18
and 5 where randomized con-
trolled trials.2-4,9,12 At 12months, the
recurrence rate after VTE pro-
voked by a transient risk factor was
4.1%per patient-year (95%CI, 3.2%-
5.0% per patient-year, fixed-effects
model; Cochran Q, P = .08 and
I2=44% for heterogeneity) for ob-
servational studies and 1.5% per pa-
tient-year (95% CI, 0.3%-2.8% per
patient-year, fixed-effects model;
Cochran Q, P=.75 and I2=0% for
heterogeneity) for randomized con-
trolled trials. The CochranQ test for
Table 2. Definition of Provoked and Unprovoked Index VTE Events
in the Source Studies
Surgical Provoking Factors
Orthopedic, general, urologic, or gynecologic surgery3
Abdominal, orthopedic, or other major surgery within 3 mo5
Surgery within 3 mo11,14
Surgery in the previous 6 wk6
Surgery with general anesthesia "30 minutes within 8 wk12
Having had VTE associated with surgery without describing the type of surgery
and the interval between surgery and when VTE was diagnosed2,4,9,10,13,15-18
Nonsurgical Provoking Factors
Various forms of immobilization within 7 d before a DVT diagnosis (trauma, traveling,
plaster on a leg, bedridden because of acute infectious disease), pregnancy, post partum5
Pregnancy or childbirth, estrogen use for contraception or hormone therapy (ongoing
or interrupted for #1 mo), recent trauma, fracture within 3 mo11
Pregnancy, postpartum events up to 2 mo after delivery, fracture, plaster cast,
estrogen-containing oral contraceptive use, immobilization, nonspecific transient illness,
history of travel6
Fracture or plaster casting of a lower limb, hospitalization with confinement to bed
for 3 consecutive days within 8 wk12
Major trauma, marked immobility within 90 d13
Pregnancy, puerperium, use of an oral contraceptive within 30 d, or trauma, immobilization,
or use of a plaster cast within 3 mo14
Pregnancy or having given birth in the previous 3 mo, estrogen use, recent (# 3 mo) leg
trauma, fracture, or bedridden for "1 wk because of a chronic medical illness16
Fracture, application of a plaster cast, use of estrogen-containing oral contraceptives,
immobilization ($3 d), nonspecific transient illness with immobilization for $3 d,
or history of travel ("6 h continuous air flight or road travel within 1 wk of onset
of symptoms)18
Having had VTE associated with a nonsurgical illness without describing the type of illness
and how long it occurred before diagnosis2-4,9,10,15,17
Abbreviations: DVT, deep venous thrombosis; VTE, venous thromboembolism.
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heterogeneity between studies of dif-
ferent design was significant
(P=.009). At 24 months, the annu-
alized recurrence rate was 3.4% per
patient-year (95%CI, 2.8%-4.0%per
patient-year; CochranQ, P=.25 and
I2=22% for heterogeneity) for ob-
servational studies and 2.5% per pa-
tient-year (95% CI, 0.8%-4.2% per
patient-year; CochranQ, P=.56 and
I2=0% for heterogeneity) for ran-
domized controlled trials. TheCoch-
ran Q test for heterogeneity be-
tween studies of different designwas
not significant (P=.38).
UNPROVOKED VTE
Patients with unprovokedVTEwere
enrolled in 11 of the 15 studies
(Table 1).During the first 12months
after stopping anticoagulant therapy,
there were 216 recurrent VTEs in
2357 patients (2228 patient-years; 9
studies2,4,6,9,10,13,14,16,18) with unpro-
vokedVTE, corresponding to an an-
nualized event rate of 7.9% per pa-
tient-year (95%CI, 4.9%-10.9% per
patient-year, random-effects model;
CochranQ, P# .001 and I2=84% for
heterogeneity). During the 0- to 24-
month interval after stopping anti-
coagulant therapy, there were 321
recurrent VTEs in 2174 patients
(3899 patient-years ; 9 stud-
ies4,6,9-11,14,16-18), corresponding to an
annualized event rate of 7.4%per pa-
tient-year (95% CI, 6.5%-8.2% per
patient-year, random-effects model;
CochranQ, P# .001 and I2=76% for
heterogeneity). The recurrence rate
was 8.2% per patient-year in stud-
ies that prospectively categorized pa-
tients as having unprovoked VTE
and 4.9% per patient-year in stud-
ies that did this retrospectively
(Cochran Q, P=.04). The rate ratio
of recurrence after unprovokedVTE
compared with (1) all patients with
VTEprovokedby a transient risk fac-
tor was 2.5 (95% CI, 2.0-3.2, fixed-
effectsmodel; CochranQ,P=.99 and
I2=0% for heterogeneity) (9 stud-
ies2,4,6,9,10,13,14,16,18) at 1 year and 2.3
(95%CI, 1.9-2.8;CochraneQ,P=.93
and I2=0% for heterogeneity) (9
studies4,6,9-11,14,16-18) at 2 years; (2) pa-
tients with a VTE provoked by sur-
gery was 7.9 (95% CI, 2.2-28.7) at
1 year (1 study6) and 10.6 (95% CI,
3.4-32.5) at 2 years (2 studies6,10);
and (3) patients with VTE pro-
voked by a nonsurgical risk factor
was 1.4 (95% CI, 0.9-2.2) at 1 year
(1 study6) and 1.8 (95% CI, 1.2-
2.5) at 2 years (2 studies6,10).
COMMENT
This analysis estimated that the rate
of recurrence after stopping treat-
ment inpatientswith symptomatic in-
dexVTEprovoked by a transient risk
factor was 3.3% during the first year
and 6.6% during the first 2 years. In
patientswith indexVTEprovokedby
a transient risk factor, the risk of re-
currencewasmuch lower (about one
third) if VTE was provoked by sur-
gery than if itwas provokedby anon-
surgical factor. Thehighest risk of re-
currence was in patients with
unprovoked VTE, who had a risk of
recurrence that was approximately
2.5-fold that of all patients with VTE
provoked by a transient risk factor,
7-fold that of patients with VTE pro-
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Figure 2. Recurrence rates of venous thromboembolism during the first year (A) and the first 2 years (B)
after stopping anticoagulant therapy in all patients with an index venous thromboembolism provoked by a
transient risk factor. Recurrence rates are calculated for individual studies and are pooled across studies.
Recurrence rates are per patient per year (ie, 0.1 corresponds to 10% of patients per year). BTS indicates
Research Committee of the British Thoracic Society; CI, confidence interval; diamonds, pooled recurrence
rate; dashed line, mean pooled recurrence rate.
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vokedby surgery, and1.5-fold that of
patientswithVTEprovokedbyanon-
surgical trigger.
This analysis has strengths and
weaknesses. Strengths include that a
thorough literature search was per-
formed to ensure that all relevant
studies were included in the analy-
sis; only prospective studies that had
satisfied predefined methodological
criteria were included; data were in-
dependently extractedby2of us (A.I.
and E.F.), which reduced the risk of
errors; data from individual studies
were combined using appropriate
meta-analytic techniques; and the
analysis includes only patients who
had symptomaticVTE (ie, it does not
include asymptomatic DVT de-
tected by screening after surgery).
Weaknesses include that (1) the defi-
nitions of provoked and unpro-
voked VTE differed among studies;
(2) many studies did not subdivide
provokedVTE into surgical andnon-
surgicalgroupsand,consequently, the
precision of the estimates for these
subgroups is reduced;moreover, pa-
tients in thenonsurgical groupare ex-
pected to be heterogenous (eg, mi-
nor trauma,medical illness), and the
risk of recurrence may differ among
thesepatients; (3)manystudies2-4,9 did
not enroll consecutive patients with
provoked VTE, and, consequently,
the patients in this analysis may not
be fully representative. The observa-
tion that some recurrence rates dif-
fered according to whether the
qualifying episode of VTE was pro-
spectively rather than retrospec-
tively categorized as being due to a
transient risk factor, and in observa-
tional studies compared with ran-
domized trials, suggests that differ-
ences in study design may have
contributed to heterogeneity of find-
ings among studies. Because we did
not include studies of patients with
unprovokedVTE that didnot also in-
clude patientswithVTEprovokedby
a transient risk factor, the estimate for
the rate of recurrence in patientswith
unprovoked VTE may be less reli-
able. Evidence suggests that factors
such as patient sex, presence of post-
thrombotic syndrome, and D-dimer
levels after stopping anticoagulant
therapy may help predict an indi-
vidual patient’s risk of recurrent VTE
after stopping therapy.19,20Wedidnot
assess the effect of these factors in the
present analysis; however, we note
that an association between such risk
factors andriskof recurrencehasbeen
observed in patients with unpro-
vokedVTEandnot in thosewithpro-
voked thrombosis.18,21
Current recommendations are to
treat patients with VTE provoked by
a transient risk factor, including
those with VTE provoked by a non-
surgical trigger, for 3 months.1 The
rate of recurrence of 5.7% in the first
year and 8.4% in the first 2 years in
patients with VTE provoked by a
transient nonsurgical factor, al-
though substantially higher than the
rate in patients with VTE provoked
by surgery, is still supportive of this
practice. The findings from this
analysis may also be helpful in the
management of patients with un-
provoked VTE.22
We suggest that whether using
clinical or laboratorymarkers, it was
possible to identify subgroups of pa-
tients with unprovoked proximal
DVT or PE with a risk of recur-
rence that was similar to, or less
than, that in patients with VTE pro-
voked by a nonsurgical factor (eg,
approximately 5% after 1 year and
8% after 2 years); anticoagulant
therapy could also be stopped in
these patients after 3months of treat-
ment. However, we acknowledge
that the risk of recurrence after stop-
ping anticoagulant therapy is only
one factor that needs to be consid-
ered when deciding on the dura-
tion of anticoagulant therapy for
VTE; the risk of bleeding during an-
ticoagulant therapy, cost of therapy,
and individual patient preferences
(ie, burden of therapy and fear of re-
currence or bleeding) also affect this
decision.
In conclusion, we confirm that
there is a low risk of recurrence af-
ter stopping anticoagulant therapy
in patients with symptomatic VTE
provoked by a reversible risk factor
and a low risk of recurrence when
VTE was provoked by recent sur-
gery. Although the risk of recur-
rence was higher if VTE was asso-
ciated with a nonsurgical risk factor
than if it was associated with recent
surgery, this risk was lower than in
patients with unprovoked VTE and
still seems to be low enough to jus-
tify stopping anticoagulant therapy
at 3 months in most such patients.
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